RecruitingNCT04567056
Specific Methylation Profiles in HNSCC
Validation of Specific Methylation Profiles Ind Head and Neck Cancer - a Cohort Study
Sponsor
Aalborg University Hospital
Enrollment
300 participants
Start Date
Sep 16, 2020
Study Type
OBSERVATIONAL
Conditions
Summary
In the study, N-20190047, the investigators aim to define specific methylation patterns in a group of patients with head and neck squamous cell carcinomas. With this study the investigators aim to validate these findings in a larger cohort.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Cancer group:
- Written informed consent
- Verified head and neck squamous cell carcinoma
- Written informed consent
- Normal ENT-examination
Exclusion Criteria7
- Other active cancer
- Uncontrolled comorbidity
- Unable to give informed consent
- Control group:
- Other active cancer
- Uncontrolled comorbidity
- Unable to give informed consent
Interventions
DIAGNOSTIC_TESTBlood sample
A separate blood sample will be taken for methylation-analyses
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04567056
Related Trials
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
NCT069800383 locations
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
NCT0680685257 locations
Study of CHS-114 in Participants With Advanced Solid Tumors
NCT0563564316 locations
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
NCT043753841 location
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
NCT06496178207 locations